Page last updated: 2024-11-04

kinetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Kinetin is a synthetic cytokinin, a class of plant hormones that promote cell division and growth. It was first discovered in 1955 from autoclaved herring sperm DNA. Kinetin has been shown to have various effects on plants, including promoting cell division, delaying senescence (aging), and promoting root growth. It can also induce the formation of adventitious buds (buds that develop from non-bud tissue) and stimulate the production of chlorophyll. Kinetin is often used in plant tissue culture and research to study the effects of cytokinins on plant growth and development. Its study is important as it allows us to understand the mechanisms of plant growth and development, which can be used to improve crop yields and develop new agricultural technologies. Kinetin is also being investigated for its potential therapeutic applications in humans, such as promoting wound healing and treating age-related diseases.'

Kinetin: A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cytokinin : A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

kinetin : A member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3830
CHEMBL ID228792
CHEBI ID27407
SCHEMBL ID15705
SCHEMBL ID23014706
MeSH IDM0047855

Synonyms (181)

Synonym
caswell no. 272d
einecs 208-382-2
n(sup 6)-furfuryladenine
cytex
n(sup 6)-(furfurylamino)purine
furfuryl(purin-6-yl)amine
hsdb 7429
kinetin (van)
epa pesticide chemical code 116801
n-(2-furanylmethyl)-1h-purin-6-amine
nsc 23119
cytokinin
BRD-K65667145-001-05-8
6046-79-3
furan-2-ylmethyl-(9h-purin-6-yl)-amine
DIVK1C_000011
KBIO1_000011
SDCCGMLS-0066627.P001
PRESTWICK3_000659
BSPBIO_000697
adenine, n-furfuryl-
2-furanmethanamine, n-1h-purin-6-yl-
n6-(furfurylamino)purine
6-(furfurylamino)purine
nsc-23119
nsc23119
n6-furfuryladenine
1h-purin-6-amine, n-(2-furanylmethyl)-
n-furfuryladenine
SPECTRUM_001064
6-furfurylaminopurine
PRESTWICK_965
NCGC00016488-01
tnp00302
cas-525-79-1
NCGC00016488-02
BPBIO1_000767
BSPBIO_002120
SPECTRUM5_001599
IDI1_000011
OPREA1_761931
PRESTWICK2_000659
AB00052172
6-furfuryladenine
kinetin
C08272
525-79-1
smr000017633
MLS000101228 ,
kinetin, plant cell culture tested, crystalline
kinetin, bioreagent, plant cell culture tested, amorphous powder
n-(furan-2-ylmethyl)-7h-purin-6-amine
H35 ,
NCGC00094553-03
NCGC00094553-02
NCGC00094553-01
NCGC00094553-04
MAYBRIDGE1_007141
KBIOGR_001339
KBIO2_006680
KBIO3_001620
KBIO2_001544
KBIO2_004112
KBIOSS_001544
SPBIO_001288
NINDS_000011
SPECTRUM2_001364
SPBIO_002618
PRESTWICK0_000659
SPECTRUM3_000610
PRESTWICK1_000659
SPECTRUM4_000820
SPECTRUM1500764
SR-01000637138-1
NCGC00094553-06
NCGC00094553-05
n-(2-furylmethyl)-1h-purin-6-amine
K-4000
kinetin, >=99.0% (hplc)
AC-11023
kinerase
CHEMBL228792 ,
chebi:27407 ,
AKOS000266263
HMS561M13
HMS500A13
K0009
HMS1570C19
HMS1921G18
HMS2097C19
(2-furylmethyl)purin-6-ylamine
furan-2-yl-methyl-(7h-purin-6-yl)-amine
dtxsid9035175 ,
dtxcid7015175
tox21_301214
NCGC00255418-01
A829154
n-(furan-2-ylmethyl)-9h-purin-6-amine
HMS2231E12
STK944589
CCG-38842
NCGC00016488-07
NCGC00016488-05
NCGC00016488-04
NCGC00016488-08
NCGC00016488-09
NCGC00016488-10
NCGC00016488-03
NCGC00016488-06
unii-p39y9652yj
p39y9652yj ,
9h-purin-6-amine, n-(2-furanylmethyl)-
n-(2-furylmethyl)-9h-purin-6-amine
AKOS008967503
F0578-0087
AB02897
kinetin [inci]
kinetin [mart.]
kinetin [mi]
kinetin [who-dd]
kinetin [hsdb]
S2316
n-(furan-2-ylmethyl)-1h-purin-6-amine
HMS3369D11
FT-0620816
CCG-208509
HY-N0160
CS-1567
AB00052172-13
SCHEMBL15705
2UY5
KS-5279
n(6)-furfuryladenine
n(6)-(furfurylamino)purine
n-(2-furanylmethyl)-7h-purin-6-amine
bdbm39302
cid_3830
smr003472578
MLS006011916
n-(2-furylmethyl)-9h-purin-6-amine #
6-[(furan-2-ylmethyl)amino]-9h-purine
mfcd00075757
AKOS025395637
us9138393, kinetin
bdbm181147
us9144538, kinetin
SR-01000622725-4
sr-01000622725
SR-01000622725-3
sr-01000637138
SR-01000637138-2
HMS3651K18
SCHEMBL23014706
kinetin, 99.0%
kinetin, vetec(tm) reagent grade, 99%
n-(2-furanylmethyl)-1h-purine-6 amine
HMS3714C19
n-[(furan-2-yl)methyl]-9h-purin-6-amine
n-furfuryl-adenine
n-1h-purin-6-yl-2-furanmethanamine
n(sup6)-(furfurylamino)purine
n(sup6)-furfuryladenine
furan-2-ylmethyl-(9h-purin-6-yl)-amin
n-(2-furylmethyl)-n-(9h-purin-6-yl)amine
SY010745
SW197051-3
DB11336
n-(2-furylmethyl)-3h-purin-6-amine
kinetin (6-furfuryladenine)
Q2251215
6-((fur-2-ylmethyl)amino)purine
BRD-K65667145-001-07-4
AC2491
6-furfuryladenine;n6-furfuryladenine
GEO-04254
2-furylmethyl-(7h-purin-6-yl)amine
2,3-difluoro-4-hydroxyphenylboronicacid
6-furfurylaminopurine (kinetin)
EN300-378089
n-[(furan-2-yl)methyl]-7h-purin-6-amine
Z372953774

Research Excerpts

Overview

Kinetin is a naturally produced cytokinin that displays strong antiproliferative activity in various human cancer cells. Kinetin riboside (KR) is a N6-substituted derivative of adenosine.

ExcerptReferenceRelevance
"Kinetin riboside is a naturally produced cytokinin that displays strong antiproliferative activity in various human cancer cells. "( Apoptosis of Kinetin Riboside in Colorectal Cancer Cells Occurs by Promoting β-Catenin Degradation.
Kang, W; Nam, T; Oh, S, 2023
)
2.72
"Kinetin is a cytokinin that mitigates the effects of oxidative stress in mammalian cells."( Integrated structural and functional analysis of the protective effects of kinetin against oxidative stress in mammalian cellular systems.
AlRemeithi, FA; Bencurova, E; Dandekar, T; Fathy, M; Howari, FM; Iqbal, J; Kodandaraman, G; Naseem, M; Othman, EM; Stopper, H; Vlachakis, D, 2020
)
1.51
"Kinetin (Kn) is a cytokinin growth factor that exerts several anti-aging and antioxidant effects on cells and organs. "( Kinetin inhibits apoptosis of aging spleen cells induced by D-galactose in rats.
An, L; Li, M; Ouyang, W; Wei, Y; Wu, X; Zheng, Y, 2014
)
3.29
"Kinetin is a plant-derived compound, which is reported to possess antiaging properties. "( Efficacy and safety of 0.1% kinetin cream in the treatment of photoaging skin.
Manuskiatti, W; Meeprathom, W; Wanitphakdeedecha, R,
)
1.87
"Kinetin is a type of plant-derived cytokinin which has been reported to control differentiation and induce apoptosis of human cells."( Kinetin inhibits proliferation of hepatic stellate cells by interrupting cell cycle and induces apoptosis by down-regulating ratio of Bcl-2/Bax.
Huang, Y; Wu, L; Zhang, ZG; Zou, J, 2015
)
2.58
"Kinetin riboside (KR) is a N6-substituted derivative of adenosine. "( Effects of kinetin riboside on proliferation and proapoptotic activities in human normal and cancer cell lines.
Barciszewski, J; Dudzik, P; Dulińska-Litewka, J; Jędrychowska, P; Laidler, P; Opałka, M; Wyszko, E, 2011
)
2.2
"Kinetin (Kn) is a synthetic cytokinin plant growth hormone having some senescence-retarding effects in plants. "( Kinetin delays the onset of ageing characteristics in human fibroblasts.
Clark, BF; Rattan, SI, 1994
)
3.17

Effects

Kinetin has been shown to modulate aging, to delay age-related physiological decline and to protect against some neurodegenerative diseases.

ExcerptReferenceRelevance
"Kinetin has been shown to modulate aging, to delay age-related physiological decline and to protect against some neurodegenerative diseases."( The plant hormone kinetin in disease therapy and healthy aging.
Artal-Sanz, M; Kadlecová, A; Maková, B; Strnad, M; Voller, J, 2019
)
1.57
"Kinetin has been shown to have anti-aging effects on several different systems, including plants and human cells. "( Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo.
Chen, TF; Chou, CY; Chou, DS; Hsiao, G; Lin, CH; Lin, KH; Shen, MY; Sheu, JR; Tzu, NH, 2003
)
2.07
"Kinetin has been shown to have anti-aging effects on several different systems including plants and human cells. "( Inhibitory mechanisms of kinetin, a plant growth-promoting hormone, in platelet aggregation.
Chen, TF; Chou, CY; Chou, DS; Hsiao, G; Lin, CH; Shen, MY; Sheu, JR, 2003
)
2.07

Treatment

Kinetin treatment led to increased oil yield and favored the production of oxygenated monoterpenes, dominated by geranial and cis-p-mentha-1(7),8-dien-ol. Kinetin may lower the risk of thromboembolic-related disorders.

ExcerptReferenceRelevance
"EDTA-kinetin hybrid treatment was found to be compatible for metal decontamination from soil, its detoxification in plants by changing its environment and restoring the essential ions for the survival of plant."( Biocompatible metal decontamination from soil using Ageratum conyzoides.
Pant, D; Sharma, V, 2018
)
0.94
"Kinetin treatment led to increased oil yield and favored the production of oxygenated monoterpenes, dominated by geranial (33.53%) and cis-p-mentha-1(7),8-dien-ol (23.69%)."( Phytochemical composition and biological activities of native and in vitro-propagated Micromeria croatica (Pers.) Schott (Lamiaceae).
Budimir, S; Mihailov-Krstev, T; Slavkovska, V; Stojičić, D; Tošić, S; Uzelac, B; Zlatković, B, 2019
)
1.24
"Kinetin treatment generally decreased chlorophyll concentration and sugar content in mycorrhizal plants as well as Na/N, Na/P Na/K, Na/Ca and Na/Mg ratios."( Influence of arbuscular mycorrhizal fungi and kinetin on the response of mungbean plants to irrigation with seawater.
Rabie, GH, 2005
)
1.31
"Co-treatment with kinetin and a synthetic SL (GR24) confirmed the antagonistic functions of SL and CK on mesocotyl elongation."( Strigolactone and cytokinin act antagonistically in regulating rice mesocotyl elongation in darkness.
Hu, Z; Ichikawa, H; Jikumaru, Y; Kyozuka, J; Nagamura, Y; Nakazono, M; Takamure, I; Tsuchida-Mayama, T; Tsutsumi, N; Yamaguchi, S; Yamauchi, T; Yang, J, 2014
)
0.73
"Treatment with kinetin may lower the risk of thromboembolic-related disorders."( Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo.
Chen, TF; Chou, CY; Chou, DS; Hsiao, G; Lin, CH; Lin, KH; Shen, MY; Sheu, JR; Tzu, NH, 2003
)
0.97
"treated with kinetin (400 ppm) for 13, 25 and 37 hr."( Studies on the role of six enzymes in the metabolism of kinetin in mustard aphid, Lipaphis erysimi (Kalt.).
Kaur, H; Rup, PJ; Sohal, SK, 2006
)
0.93

Toxicity

ExcerptReferenceRelevance
" On mice with leukaemia P388, this product has no effect on the tumour growth, and it appears to be toxic at the dose of 25 mg/kg."( Cytotoxic effects of kinetin riboside on mouse, human and plant tumour cells.
Bos, R; Griffaut, B; Ledoigt, G; Madelmont, JC; Maurizis, JC, 2004
)
0.64
" In Experiment 2, intra-yolk-sac administration of toxic doses of FA (2 m m) concurrent with kinetin at 50, 100 or 200 µ m were evaluated on hatched embryos."( Assessment of the effect of kinetin against formic acid toxicity in chicken embryo model.
Allymehr, M; Amini, M; Zadeh-Hashem, E, 2023
)
1.42

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic properties were characterized in mice following analysis by liquid chromatography-tandem mass spectrometry."( In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P, 2005
)
0.33
" Oral dosing of CYC202 gave active concentrations in the tumor, modulation of pharmacodynamic markers, and inhibition of tumor growth."( In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P, 2005
)
0.33
" Pharmacodynamic markers are altered in vitro and in vivo, consistent with the inhibition of cyclin-dependent kinases."( In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
" Proline analogues azetidine-2-carboxylate and hydroxyproline in combination with standardized FPH were used to stimulate proline synthesis and benzyladenine-induced shoot organogenesis by exploiting the proposed proline-linked pentose phosphate pathway (PPP)."( Stimulation of benzyladenine-induced in vitro shoot organogenesis and endogenous proline in melon (Cucumis melo L.) by fish protein hydrolysates in combination with proline analogues.
Haynesworth, K; Kellett, G; Milazzo, MC; Shetty, K; Zheng, Z, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
" CYC202 displayed the slowest clearance from plasma and the highest tumor uptake, with oral bioavailability of 86%."( In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P, 2005
)
0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Based on these studies, a dosing regimen was developed for CYC202 that allowed therapeutic exposures in the HCT116 tumor xenograft."( In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P, 2005
)
0.33
" Oral dosing of CYC202 gave active concentrations in the tumor, modulation of pharmacodynamic markers, and inhibition of tumor growth."( In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P, 2005
)
0.33
" This chapter provides some basic concepts important to the statistical analysis of data obtained from plant tissue culture or biotechnological experiments, and illustrates the application of common statistical procedures to analyze binomial, count, and continuous data for experiments with different treatment factors as well as identifying trends of dosage treatment factors."( Use of statistics in plant biotechnology.
Compton, ME, 2006
)
0.33
" In the highest dosing cohorts (23."( Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing.
Axelrod, FB; Gold-von Simson, G; Goldberg, JD; Leyne, M; Mull, J; Rolnitzky, LM; Slaugenhaupt, SA; Voustianiouk, A, 2009
)
1.8
" Here the hypothesis is tested that the level of WEE1 has a dosage effect on growth and development in Arabidospis thaliana."( Gene dosage effect of WEE1 on growth and morphogenesis from arabidopsis hypocotyl explants.
Albani, D; Bitonti, MB; Doonan, JH; Francis, D; Herbert, RJ; Lentz Grønlund, A; Marchbank, AM; Nieuwland, J; Perrotta, L; Rogers, HJ; Siciliano, I; Spadafora, N, 2012
)
0.38
"There is a gene dosage effect of WEE1 on morphogenesis from hypocotyls both in vitro and in vivo."( Gene dosage effect of WEE1 on growth and morphogenesis from arabidopsis hypocotyl explants.
Albani, D; Bitonti, MB; Doonan, JH; Francis, D; Herbert, RJ; Lentz Grønlund, A; Marchbank, AM; Nieuwland, J; Perrotta, L; Rogers, HJ; Siciliano, I; Spadafora, N, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
cytokininA phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
6-aminopurinesAny compound having 6-aminopurine (adenine) as part of its structure.
furansCompounds containing at least one furan ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
cytokinins 7-N-glucoside biosynthesis014
cytokinins 9-N-glucoside biosynthesis015
cytokinin-O-glucosides biosynthesis614
cytokinins 7-N-glucoside biosynthesis219
cytokinins 9-N-glucoside biosynthesis217
cytokinin-O-glucosides biosynthesis615
Cytokinins conjugates biosynthesis08
Cytokinins 9-N-glucoside biosynthesis014

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency25,118.90040.003245.467312,589.2998AID2517
15-lipoxygenase, partialHomo sapiens (human)Potency25.11890.012610.691788.5700AID887
GLI family zinc finger 3Homo sapiens (human)Potency30.63790.000714.592883.7951AID1259369
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency61.13060.001022.650876.6163AID1224893
estrogen nuclear receptor alphaHomo sapiens (human)Potency72.27380.000229.305416,493.5996AID1259244; AID1259248; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency24.54120.001019.414170.9645AID743191
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID902
histone deacetylase 9 isoform 3Homo sapiens (human)Potency68.58960.037617.082361.1927AID1259364; AID1259388
gemininHomo sapiens (human)Potency0.43890.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency10.00000.125912.234435.4813AID1458
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, EndochitinaseSaccharomyces cerevisiae (brewer's yeast)Ki3.20003.2000208.0667600.0000AID977610
Chain A, EndochitinaseSaccharomyces cerevisiae (brewer's yeast)Ki3.20003.2000208.0667600.0000AID977610
Chain A, EndochitinaseSaccharomyces cerevisiae (brewer's yeast)Ki3.20003.2000208.0667600.0000AID977610
EndochitinaseSaccharomyces cerevisiae S288CKi3.20000.61001.90503.2000AID539001
7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)IC50 (µMol)24.50000.05201.20935.6000AID1802795
Acidic mammalian chitinaseHomo sapiens (human)IC50 (µMol)1,000.00000.04002.27004.5000AID539003
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
purine nucleoside catabolic process7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA repair7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to oxidative stress7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
male gonad development7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA protection7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to cadmium ion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
polysaccharide catabolic processAcidic mammalian chitinaseHomo sapiens (human)
immune system processAcidic mammalian chitinaseHomo sapiens (human)
production of molecular mediator involved in inflammatory responseAcidic mammalian chitinaseHomo sapiens (human)
chitin metabolic processAcidic mammalian chitinaseHomo sapiens (human)
chitin catabolic processAcidic mammalian chitinaseHomo sapiens (human)
apoptotic processAcidic mammalian chitinaseHomo sapiens (human)
positive regulation of chemokine productionAcidic mammalian chitinaseHomo sapiens (human)
polysaccharide digestionAcidic mammalian chitinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
5'-(N(7)-methylguanosine 5'-triphospho)-[mRNA] hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
protein binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
dATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
snoRNA binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
metal ion binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
ATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-dATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
N6-methyl-(d)ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
O6-methyl-dGTP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
chitinase activityAcidic mammalian chitinaseHomo sapiens (human)
protein bindingAcidic mammalian chitinaseHomo sapiens (human)
kinase bindingAcidic mammalian chitinaseHomo sapiens (human)
chitin bindingAcidic mammalian chitinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
acrosomal vesicle7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
extracellular space7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nucleus7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrial matrix7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytosol7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nuclear membrane7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
extracellular regionAcidic mammalian chitinaseHomo sapiens (human)
extracellular spaceAcidic mammalian chitinaseHomo sapiens (human)
cytoplasmAcidic mammalian chitinaseHomo sapiens (human)
extracellular regionAcidic mammalian chitinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1395661Anti-senescent activity in leaf of Triticum aestivum cv. Hereward seedlings by measuring chlorophyll retention at 10'-4 mol/L after 4 days relative to control2018European journal of medicinal chemistry, Apr-25, Volume: 150New cytokinin derivatives possess UVA and UVB photoprotective effect on human skin cells and prevent oxidative stress.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1383084Cytotoxicity against human THP1 cells assessed as cell viability at 10 uM by CellTiter-Glo luminescent assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis and ability of non-gold complexed substituted purine derivatives to inhibit LPS-induced inflammatory response.
AID1719349Apparent permeability of compound in human Caco2 cells2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Cytoprotective activities of kinetin purine isosteres.
AID1395658Growth promoting activity in tobacco callus assessed as callus weight at 10'-5 mol/L after 4 weeks relative to control2018European journal of medicinal chemistry, Apr-25, Volume: 150New cytokinin derivatives possess UVA and UVB photoprotective effect on human skin cells and prevent oxidative stress.
AID1395657Antioxidant activity assessed as trolox equivalent of AAPH-induced radical scavenging activity at 1 uM pretreated for 15 mins followed by APPH challenge measured every 3 mins over 90 mins by ORAC-FL assay2018European journal of medicinal chemistry, Apr-25, Volume: 150New cytokinin derivatives possess UVA and UVB photoprotective effect on human skin cells and prevent oxidative stress.
AID1175339Inhibition of collagen-induced human platelet aggregation after 3 mins by light transmission aggregometry2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Naturally occurring N(6)-substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: an in silico evaluation of their interaction with the P2Y(12) receptor.
AID1719348Apparent permeability of the compound at 20 uM after 18 hrs by PAMPA2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Cytoprotective activities of kinetin purine isosteres.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID539001Inhibition of Saccharomyces cerevisiae CTS12010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Acetazolamide-based fungal chitinase inhibitors.
AID1719343Stability in human plasma assessed as parent compound remaining at 2 uM measured up to 120 mins by RF-MS analysis2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Cytoprotective activities of kinetin purine isosteres.
AID1481725Activation of FLAG tagged PINK1 (unknown origin) expressed in Flp-In TRex HEK293 cells co-expressing wild-type Parkin assessed as Parkin Ser65 phosphorylation at 50 uM after 24 hrs in absence of CCCP by immunoblotting analysis2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization.
AID1395653Cytoprotection against phototoxicity in human NHDF cells assessed as increase in cell viability at 3.9 to 31.3 uM preincubated for 60 mins followed by 150 mJ/cm2 UVB irradiation and measured after 24 hrs by neutral red uptake assay2018European journal of medicinal chemistry, Apr-25, Volume: 150New cytokinin derivatives possess UVA and UVB photoprotective effect on human skin cells and prevent oxidative stress.
AID1383086Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production at 10 uM pretreated for 2 hrs followed by LPS stimulation measured after over night incubation by ELISA relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis and ability of non-gold complexed substituted purine derivatives to inhibit LPS-induced inflammatory response.
AID1395659Growth promoting activity in Amaranthus caudatus var. atropurpurea seeds by measuring betacyanin at 10'-5 mol/L after 48 hrs relative to control2018European journal of medicinal chemistry, Apr-25, Volume: 150New cytokinin derivatives possess UVA and UVB photoprotective effect on human skin cells and prevent oxidative stress.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID539003Inhibition of human chitinase2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Acetazolamide-based fungal chitinase inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1395647Cytoprotection against phototoxicity in human NHDF cells assessed as increase in cell viability at 3.9 to 31.3 uM preincubated for 60 mins followed by 7.5 J/cm2 UVA irradiation and measured after 24 hrs by neutral red uptake assay2018European journal of medicinal chemistry, Apr-25, Volume: 150New cytokinin derivatives possess UVA and UVB photoprotective effect on human skin cells and prevent oxidative stress.
AID1719344Stability in human liver microsomes assessed as parent compound remaining at 2 uM measured up to 60 mins by RF-MS analysis2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Cytoprotective activities of kinetin purine isosteres.
AID539002Inhibition of Aspergillus fumigatus ChiA1 expressed in Pichia pastoris after 70 mins2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Acetazolamide-based fungal chitinase inhibitors.
AID1719350Apparent permeability of compound in MDCK-MDR1 cells2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Cytoprotective activities of kinetin purine isosteres.
AID1383085Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production at 10 uM pretreated for 2 hrs followed by LPS stimulation measured after over night incubation by ELISA relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis and ability of non-gold complexed substituted purine derivatives to inhibit LPS-induced inflammatory response.
AID1719347Protein binding in human plasma at 10 uM after 4 hrs by RF-MS analysis2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Cytoprotective activities of kinetin purine isosteres.
AID290333Antiproliferative activity against human HL60 cells2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and biological evaluation of 7-azaindole derivatives, synthetic cytokinin analogues.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802795In Vitro MTH1 Enzymatic Assay from Article 10.1111/cbdd.12909: \\Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.\\2017Chemical biology & drug design, 06, Volume: 89, Issue:6
Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2007Chemistry & biology, May, Volume: 14, Issue:5
Structure of Saccharomyces cerevisiae chitinase 1 and screening-based discovery of potent inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (860)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990114 (13.26)18.7374
1990's130 (15.12)18.2507
2000's341 (39.65)29.6817
2010's224 (26.05)24.3611
2020's51 (5.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.29 (24.57)
Research Supply Index6.83 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index97.68 (26.88)
Search Engine Supply Index2.89 (0.95)

This Compound (42.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.22%)5.53%
Reviews18 (1.95%)6.00%
Case Studies1 (0.11%)4.05%
Observational0 (0.00%)0.25%
Other900 (97.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Kinerase® Interactive Skin-care Study: A Multicentre, Phase IV, Single-arm, Open-label Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Facial Photodamage [NCT01885091]Phase 4100 participants (Actual)Interventional2012-12-31Completed
[NCT00492479]Phase 40 participants Interventional2007-06-30Terminated
The Safety and Tolerability of Kinetin, a Nutritional Supplement That Corrects the Splicing Defect, in Patients With Familial Dysautonomia [NCT02274051]Phase 115 participants (Actual)Interventional2009-11-30Completed
A Single Arm, Phase IV, Open-Label, Split-Face Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Photoaging [NCT01898182]Phase 4132 participants (Actual)Interventional2013-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]